<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04016805</url>
  </required_header>
  <id_info>
    <org_study_id>UTX-TGR-208</org_study_id>
    <nct_id>NCT04016805</nct_id>
  </id_info>
  <brief_title>Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax</brief_title>
  <official_title>A Phase 2 Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib or Venetoclax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TG Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TG Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2, two cohort trial evaluating the addition of ublituximab and umbralisib on the rate
      of minimal residual disease (MRD) negativity in subjects with Chronic Lymphocytic Leukemia
      (CLL), who are currently on treatment with ibrutinib or venetoclax.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2 open label, two treatment cohort trial evaluating the addition of
      ublituximab and umbralisib on the rate of minimal residual disease (MRD) negativity in
      subjects with CLL, who fail to achieve MRD negativity, after a minimum 6-month treatment with
      ibrutinib or venetoclax.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of minimal residual disease negativity</measure>
    <time_frame>24 months</time_frame>
    <description>Assess the rate of undetectable minimal residual disease (U-MRD)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>24 months</time_frame>
    <description>Objective response in subjects treated on study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events that are Related to Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Number of Participants With Treatment-Related Adverse Events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
umbralisib: 800 mg; to be administered daily
ibrutinib: dose tolerated by subject; to be administered daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ublituximab: 900 mg; to be administered once every cycle through cycle 6, then every 3 cycles thereafter
umbralisib: 800 mg; to be administered daily
venetoclax: dose tolerated by subject; to be administered daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ublituximab</intervention_name>
    <description>recombinant chimeric anti-CD20 monoclonal antibody
administered as an IV infusion</description>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>TG-1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Umbralisib</intervention_name>
    <description>Phosphoinositide-3-kinase (PI3K) delta inhibitor
Tablet form, to taken orally on a daily basis</description>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>TGR-1202</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib</intervention_name>
    <description>Bruton Tyrosine Kinase (BTK) inhibitor
Tablet form, to taken orally on a daily basis</description>
    <arm_group_label>ublituximab + umbralisib + ibrutinib</arm_group_label>
    <other_name>Imbruvica</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>BCL-2 inhibitor
Tablet form, to be taken orally</description>
    <arm_group_label>ublituximab + umbralisib + venetoclax</arm_group_label>
    <other_name>Venclexta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Chronic Lymphocytic Leukemia (CLL) who have been on treatment for at
             least 6 months

          -  Minimal Residual Disease positive at screening

          -  Adequate organ system function as specified in the protocol

          -  Ability to follow protocol procedures.

        Exclusion Criteria:

          -  Subjects receiving cancer therapy or any investigational drug within 21 days of Cycle
             1, Day 1.

          -  Subjects with a known histological transformation

          -  Active Hepatitis B or Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>TG Therapeutics Clinical Support Team</last_name>
    <phone>212-554-4484</phone>
    <email>clinicalsupport@tgtxinc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TG Therapeutics Investigational Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2019</study_first_submitted>
  <study_first_submitted_qc>July 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>umbralisib</keyword>
  <keyword>ublituximab</keyword>
  <keyword>venetoclax</keyword>
  <keyword>ibrutinib</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

